Clinical trials: Intravenous Therapy
Nasopharyngeal Carcinoma, Leucogen
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Toxic and side effects during and after chemoradiotherapy for nasopharyngeal carcinoma seriously affect patients' treatment compliance and long-term quality of life.
- Conditions
- Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
- Trial name
- NCT05780294
- Testing
- 5-fu, Lobaplatin, leucogen
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Cocaine-Related Disorders, Drug Administration Schedule
Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1
The purpose of this study is to evaluate modafinil, a cocaine treatment medication, and its interactions with intravenous (IV) cocaine.
- Conditions
- Cocaine-Related Disorders, Drug Administration Schedule, Infusions, Intravenous
- Trial name
- NCT00033046
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Postoperative, Delirium
Dexmedetomidine for the Treatment of Delirium After Heart Surgery
Primary hypothesis: Dexmedetomidine is equal or superior to haloperidol and placebo in the treatment of psychomotor confusion in patients who are recovering from heart surgery.
- Conditions
- Postoperative, Delirium, Psychomotor, Confusion
- Trial name
- DexinDelir (NCT01140529)
- Testing
- Dexmedetomidine, Haloperidol, Saline
- Where
- Sweden
- Volunteers
- 3 people
- Sponsor
- Thorax-Kärlkliniken
Lock Solution, Catheter Related Blood Stream Infections
Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci
Implantable venous access port infections are mainly due to coagulase negative staphylococci and may be managed by antibiotic lock therapy with retention of the port. Most of the time a vancomycin lock is used.
- Conditions
- Lock Solution, Catheter Related Blood Stream Infections, Central Venous Catheter Infection, Intravenous Drug Delivery Systems
- Trial name
- Etha-LOCK (NCT02411331)
- Testing
- Ethanol 40% + Enoxaparine 400UI/ml, Vancomycine 5 mg/ml + Héparine 2500UI/ml
- Where
- France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Kidney Disease, Chronic Heart Failure
Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease
Recently, growing body of evidence support the finding that anemia frequently occurs in patients with chronic heart failure (CHF).
- Conditions
- Chronic Kidney Disease, Chronic Heart Failure, Anemia
- Trial name
- NCT00384657
- Testing
- iron sucrose
- Where
- 2 sites in Romania
- Sponsor
- Anemia Working Group Romania
Solid Tumors
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multi-center, Phase Ib clinical study of cergutuzumab amunaleukin, in combination with atezolizumab, to investigate the safety, pharmacokinetics, and therapeutic activity in participants with locally…
- Trial name
- NCT02350673
- Testing
- Atezolizumab, Cergutuzumab Amunaleukin
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche
Gram-negative Bacterial Infection
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
This study will assess the pharmacokinetics, safety, and tolerability of single and multiple doses of intravenous ceftazidime-avibactam in hospitalized infants and neonates from 26 weeks gestation to 3 months of age.
- Trial name
- NOOR (NCT04126031)
- Testing
- Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
- Where
- 18 sites in United States, Estonia and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
COVID, SARS-CoV2 Infection
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin…
- Conditions
- COVID, SARS-CoV2 Infection, Covid19
- Trial name
- OTAC (NCT04910269)
- Testing
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 741 people
- Sponsor
- University of Minnesota
Opioid Dependence
Aprepitant Effects in Intravenous Heroin Dependence
Current treatments for opioid addiction would benefit by the addition of a non-opioid based treatment medication. Recent behavioral studies have shown that the neurokinin-1 (NK1) receptor is involved in opioid reward and…
- Trial name
- NCT01527994
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- NYU Langone Health
CCHF
UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
UMIT-1: A Randomised Phase Ib Study to Determine the Phase II dose and to Evaluate the Safety and Efficacy of intravenous (IV) Favipiravir \& Ribavirin for the Treatment of CCHF
- Trial name
- UMIT-1 (NCT05940545)
- Testing
- Favipiravir, Ribavirin
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Liverpool School of Tropical Medicine
Parkinson's Disease, Gaucher's Disease
Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
The investigators are interested in determining if the investigators are able to detect changes in brain chemistry using Magnetic Resonance Spectroscopy (MRS) in individuals with Parkinson's disease (PD), those with Gaucher's…
- Trial name
- NCT01427517
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
HER 2 Positive Advanced Breast Cancer
HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy
1. The primary goal of this clinical trial is to evaluate the pathological complete response (pCR) rate of oral paclitaxel solution combined with subcutaneous pertuzumab and trastuzumab in the neoadjuvant treatment of early or…
- Trial name
- NCT07848633
- Testing
- - Oral paclitaxel solution: 200 mg/m² orally twice daily on Day 1 and Day 8 of each cycle, subcutaneous pertuzumab and trastuzumab fixed-dose combination for a total of 6 cycles
- Volunteers
- 65 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Anesthesia
Postdural Puncture Headache Relief With Aminophylline and SPGB
The purpose of the study is to compare Sphenopalatine ganglion block (SPGB) and aminophylline in the efficacy and safety management of PDPH.
- Trial name
- NCT05552404
- Testing
- conservative therapy, Aminophylline, trans nasal sphenopalatine ganglion block
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Acute Ischemic Stroke
Intravenous Thrombolysis and NOAC
New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT06749834
- Testing
- Intravenous thrombolysis
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Iron-deficiency
Imaging Intravenous Iron
The aim of this study is to track where the iron goes in different tissues in the hours, days and weeks after an intravenous iron infusion.
- Trial name
- NCT05609318
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Skin Structures and Soft Tissue Infections
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
- Trial name
- REVIVE-2 (NCT02607618)
- Testing
- Iclaprim, Vancomycin
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 613 people
- Sponsor
- Motif Bio
Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
This clinical trial is designed to evaluate KELI-101 versus placebo for the prevention of acute kidney disease leading to chronic kidney disease in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- MesAKI (NCT06678399)
- Testing
- KELI-101
- Volunteers
- 91 people
- Sponsor
- Kelifarma
Sleep Disorders, Sciatica
Intravascular Laser and Electroacupuncture for Sciatica With Insomnia: A Pilot Trial
Sciatica is a common condition worldwide, with prevalence rates ranging from 1.2% to 43%. Chronic sciatica is often associated with sleep disturbances, forming a bidirectional loop where persistent nociceptive input disrupts…
- Trial name
- NCT06755593
- Testing
- Electroacupuncture, Intravascular Low-Level Laser Therapy (ILIB)
- Where
- Vietnam
- Volunteers
- 66 people
- Sponsor
- Le Hoang Minh Quan
Homozygous Familial Hypercholesterolemia
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR…
- Trial name
- NCT06125847
- Testing
- NGGT006
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Solid Tumor
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.
- Trial name
- NCT05798533
- Testing
- Neo-T, Toripalimab, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- BGI, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.